There are specific treatment options patients may qualify for depending on the cytogenetic or molecular abnormality detected.
Katelyn Yamartino, PharmD
Advertisement
Articles by Katelyn Yamartino, PharmD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Panel Unanimously Backs Moderna’s Breakthrough mRNA Flu Vaccine Amid Political Turbulence
2
Sonrotoclax Plus Zanubrutinib Achieves Undetectable MRD Rates Above 90% in Frontline CLL/SLL
3
Are Non-Opioid Therapies Finally Challenging Opioids in Acute Pain Management?
4
McKesson ideaShare 2026: How AI and Automation Are Reshaping the Dispensing Experience
5